论文部分内容阅读
目的 :提高慢性乙型肝炎抗病毒药物的治疗效果 ,拓宽用药途径。方法 :口服拉米夫定的同时口服免疫调节剂胸腺肽肠溶胶囊 (联合组 ) ,联合组口服拉米夫定 10 0mg/天 ,疗程为 12个月 ;口服胸腺肽肠溶胶囊 15mg ,2次 /天 ,疗程为 6个月 ,并与单用拉米夫定者进行对比观察。 结果 :经 3、6、9、12个月治疗后 ,HBeAg阳性、抗 HBe阴性的转换率分别比单用拉米夫定组上升 10 0 %～ 15 0 % ,两者比较 ,差异显著 (P <0 0 5 )。两组HBV DNA的转阴率相比较 ,无显著差异 (P >0 0 5 )。结论 :拉米夫定联合胸腺肽肠溶胶囊治疗乙肝疗效确切 ,且服用方便、费用低。
Objective: To improve the therapeutic effect of chronic hepatitis B antiviral drugs and to broaden the use of drugs. Methods: oral administration of lamivudine oral administration of thymosin enteric-coated immunosuppressant (combination group), the combined group oral lamivudine 10 0mg / day, course of treatment for 12 months; oral administration of thymosin enteric-coated capsules 15mg, 2 times / Day, course of treatment for 6 months, and compared with lamivudine alone for observation. Results: After 3, 6, 9 and 12 months of treatment, the conversion rate of HBeAg positive and anti HBe negative was 100% ~ 150% higher than that of lamivudine alone group, the difference was significant (P <0 0 5). There was no significant difference in the negative conversion rate of HBV DNA between the two groups (P> 0.05). Conclusion: lamivudine combined with thymosin enteric-coated capsules treatment of hepatitis B effect is exact, and easy to take, low cost.